Literature DB >> 23228095

Prescription patterns of pain medicine physicians.

Honorio T Benzon1, Mark C Kendall, Jeffrey A Katz, Hubert A Benzon, Khalid Malik, Paul Cox, Kathryn Dean, Michael J Avram.   

Abstract

OBJECTIVES: Our study surveyed physician members of 3 American pain societies to determine prescription patterns and whether these practices reflect current expert opinion.
METHODS: We sent 3 mailings to 2938 physicians from January 2010 to January 2011. The questionnaire contained 49 questions on topics related to opioids, antidepressants, anticonvulsants, and preferences for the different pain syndromes.
RESULTS: A total of 474 physicians responded, representing a 16% return. Seventy-two percent ask patients to sign an opioid agreement, 59% order random urine drug testing, 13% wait until the dose of methadone is between 100 and 150 mg before converting the drug to another opioid, and 85% do not think there is a maximum dose of opioids with respect to driving. Most responders prescribe codeine to Caucasians and Asians. While 42% stated that the maximum daily dose of acetaminophen is 3000 mg, 75% would decrease the dose in patients who are moderate or heavy drinkers. Fifty-four percent do not order an ECG at all when prescribing tricyclic antidepressants.
CONCLUSIONS: The responses pertaining to opioid agreements, urine drug testing, acetaminophen, and treatment for neuropathic pain are reassuring in that they prevent misuse and abuse of opioids, prevent acetaminophen-induced hepatotoxicity, and reflect evidence-based treatments. However, we identified gaps in knowledge, including the prescription of codeine in certain populations and the use of electrocardiogram in patients on antidepressants. Further education of physicians who treat chronic pain pharmacologically is warranted.
© 2012 The Authors Pain Practice © 2012 World Institute of Pain.

Entities:  

Keywords:  analgesics; neuropathic pain; non-narcotic analgesics; opioid agreements; opioids; prescription patterns; urine drug screening

Mesh:

Substances:

Year:  2012        PMID: 23228095     DOI: 10.1111/papr.12011

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  5 in total

1.  Response to Urine Drug Testing in a Family Residency Practice.

Authors:  Michael G McDonell; Imara I West; Richard K Ries; Dennis M Donovan; Kristin Bumgardner; Chris Dunn; David C Atkins; Peter Roy-Byrne; Charles Maynard
Journal:  J Addict Med       Date:  2017 May/Jun       Impact factor: 3.702

2.  Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis.

Authors:  E Jennifer Edelman; Kirsha S Gordon; Vincent Lo Re; Melissa Skanderson; David A Fiellin; Amy C Justice
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-09-22       Impact factor: 2.890

3.  Provider Misinterpretation, Documentation, and Follow-Up of Definitive Urine Drug Testing Results.

Authors:  Isaac Chua; Athena K Petrides; Gordon D Schiff; Jaime R Ransohoff; Michalis Kantartjis; Jocelyn Streid; Christiana A Demetriou; Stacy E F Melanson
Journal:  J Gen Intern Med       Date:  2019-11-11       Impact factor: 5.128

4.  Patient therapeutic education: placing the patient at the centre of the WHO analgesic ladder.

Authors:  Grisell Vargas-Schaffer; Jennifer Cogan
Journal:  Can Fam Physician       Date:  2014-03       Impact factor: 3.275

5.  Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations.

Authors:  Charles E Argoff; Daniel P Alford; Jeffrey Fudin; Jeremy A Adler; Matthew J Bair; Richard C Dart; Roy Gandolfi; Bill H McCarberg; Steven P Stanos; Jeffrey A Gudin; Rosemary C Polomano; Lynn R Webster
Journal:  Pain Med       Date:  2018-01-01       Impact factor: 3.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.